Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024
Rhea-AI Summary
Assertio Holdings, Inc. (Nasdaq: ASRT), a pharmaceutical company, has announced it will release its second quarter 2024 financial results on Wednesday, August 7, 2024, after the market close. The company will host a live webcast earnings conference call at 4:30 p.m. Eastern Time following the release.
Investors can access the webcast and related materials through Assertio's investor relations website. For those joining by telephone, the dial-in number is +1-646-307-1963 with call ID 4674653. A webcast replay will be available approximately two hours after the call on the company's investor website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ASRT declined 3.29%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release second quarter 2024 financial results on Wednesday, August 7, 2024, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wishing to join by telephone only, please dial +1-646-307-1963. The call ID is 4674653.
A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website.
About Assertio
Assertio is a commercial pharmaceutical company offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. To learn more about Assertio, visit www.assertiotx.com.
Investor Contact
Matt Kreps
Darrow Associates Investor Relations
+1-214-597-8200
mkreps@darrowir.com